Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00430781 · ClinicalTrials.gov registry record · Phase 2

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

A Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
228
Enrollment target
20
Study locations

NCT00430781 is a Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix that has completed, run by GlaxoSmithKline. The registered enrollment target is 228 participants, above the 75-participant average among 4 other Metastatic Cervical Cancer trials with a reported enrollment target (204% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00430781, a Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
228 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

Conditions Studied

Metastatic Cervical Cancer Neoplasms, Uterine Cervix

Interventions

  • DRUG pazopanib (GW786034)
  • DRUG lapatinib (GW572016)

Study Locations (20)

California

  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Orange
  • GSK Investigational Site - Stanford

Ohio

  • GSK Investigational Site - Cleveland
  • GSK Investigational Site - Columbus

Buenos Aires

  • GSK Investigational Site - Capital Federal
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aires

Santa Fe Province

  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Santa Fe

Other

  • GSK Investigational Site - Quilmes
  • GSK Investigational Site - Brussels

Georgia

  • GSK Investigational Site - Augusta

Massachusetts

  • GSK Investigational Site - Boston

New Mexico

  • GSK Investigational Site - Albuquerque

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2006-11
Est. Completion 2011-07
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00430781

The ClinicalTrials.gov registry entry for NCT00430781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 4 other Metastatic Cervical Cancer trials with a reported enrollment target (204% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which pazopanib (GW786034) is the first listed.

NCT00430781 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Buenos Aires.

Frequently Asked Questions

What is clinical trial NCT00430781 about?

NCT00430781 is a clinical study titled "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer". This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

What is the current status of trial NCT00430781?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2006-11. Estimated completion is 2011-07.

What conditions does trial NCT00430781 study?

This clinical trial studies the following conditions: Metastatic Cervical Cancer, Neoplasms, Uterine Cervix.

What interventions are being tested in trial NCT00430781?

The interventions under investigation include: pazopanib (GW786034) (DRUG), lapatinib (GW572016) (DRUG).

Who is sponsoring clinical trial NCT00430781?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00430781 being conducted?

This trial has 20 study locations across California, Georgia, Massachusetts, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Cervical Cancer

All registered trials for this condition

Neoplasms, Uterine Cervix

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.